Rhodococcus bacteria as a source of novel antibiotics

在过去的25年里，新抗生素的发现率直线下降。在同一时期，对目前已知的许多抗生素具有耐药性的细菌迅速增加，使这一问题更加复杂。目前，医学、农业和兽医治疗中用于治疗细菌感染的大多数抗生素都来自链霉菌属细菌。希望其他放线菌属如红球菌具有与链霉菌相同的能力。这个项目的想法是将红球菌作为新型抗生素的来源，因为它们也是放线菌，并且与链霉菌具有类似的遗传潜力，这可能表明存在抗菌化合物生产。链霉菌的调控系统最近已被表征，据信在红球菌基因组中发现了类似的调控系统。这项研究的目的是了解红球菌途径的调控，最终导致发展

In the last 25 years the discovery rate of new antibiotics has plummeted. In the same time period, this problem has been compounded by the rapid rise of drug resistant bacteria for many of the antibiotics that are currently known. At the moment, the majority of the antibiotics that are used to treat bacterial infections in medicine, agriculture and veterinarian treatment originate from the bacterial genus Streptomyces. It is hoped that other actinomycetes genera such as Rhodococcus have the same capability as the Streptomyces. The idea of this project is to look at Rhodococcus bacteria as a source for novel antibiotics due to them also being actinomycetes and having analogous genetic potential to Streptomyces that may indicate the presence of antimicrobial compound production. The regulatory system in Streptomyces has recently been characterised and it is believed that there is an analogue of this found in the Rhodococcus genome. The aim of this study is to understand the regulation of the Rhodococcus pathways that will ultimately lead to the development